Nordic Nanovector appoints Sandra Jonsson as COO
Nordic Nanovector (OTCPK:NRNVF) has appointed Sandra Jonsson, PhD, MBA as Chief Operating Officer effective 10 January 2022 and takes over from Marco Renoldi, MD, who is retiring from the role but will remain as a consultant to the company.
Dr Jonsson is a results-driven international Life Science executive, with >15 years of cross-functional experience in global pharmaceutical and biotechnology companies.
Dr Jonsson most recently served as Senior Director for Alexion Pharmaceuticals.